Anti-NDRG1 antibody
| Name | Anti-NDRG1 antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab37897 |
| Prices | $385.00 |
| Sizes | 100 µg |
| Host | Goat |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | WB ELISA IHC-P |
| Species Reactivities | Human, Mouse, Rat, Dog |
| Antigen | Synthetic peptide: GNSAGPKSMEVSC , corresponding to C terminal amino acids 382-394 of Human NDRG1 Run BLAST with Run BLAST with |
| Description | Goat Polyclonal |
| Gene | NDRG1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Anti-NDRG1 antibody (ab37897) at 0.1 µg/ml + Human Kidney lysate (RIPA buffer, 35µg total protein per lane).
Product References
The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits - The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits
Sahni S, Bae DH, Lane DJ, Kovacevic Z, Kalinowski DS, Jansson PJ, Richardson DR. J Biol Chem. 2014 Apr 4;289(14):9692-709.
The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear - The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear
Jin R, Liu W, Menezes S, Yue F, Zheng M, Kovacevic Z, Richardson DR. J Cell Sci. 2014 Jul 15;127(Pt 14):3116-30.
Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell - Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell
Shi ZH, Shi FF, Wang YQ, Sheftel AD, Nie G, Zhao YS, You LH, Gou YJ, Duan XL, Zhao BL, Xu HM, Li CY, Chang YZ. Cell Mol Life Sci. 2015 Mar;72(5):983-97.
Acute mTOR inhibition induces insulin resistance and alters substrate utilization - Acute mTOR inhibition induces insulin resistance and alters substrate utilization
Kleinert M, Sylow L, Fazakerley DJ, Krycer JR, Thomas KC, Oxboll AJ, Jordy AB, Jensen TE, Yang G, Schjerling P, Kiens B, James DE, Ruegg MA, Richter EA. Mol Metab. 2014 Jun 27;3(6):630-41.
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor - N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor
Lane DJ, Saletta F, Suryo Rahmanto Y, Kovacevic Z, Richardson DR. PLoS One. 2013;8(2):e57273.
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral - The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral
Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR. Mol Pharmacol. 2013 Jan;83(1):179-90.
Targeting the metastasis suppressor, NDRG1, using novel iron chelators: - Targeting the metastasis suppressor, NDRG1, using novel iron chelators:
Sun J, Zhang D, Zheng Y, Zhao Q, Zheng M, Kovacevic Z, Richardson DR. Mol Pharmacol. 2013 Feb;83(2):454-69.
Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor - Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor
Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, Richardson DR. Br J Cancer. 2013 Feb 5;108(2):409-19.
Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but - Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but
Ghalayini MK, Dong Q, Richardson DR, Assinder SJ. Biosci Rep. 2013 Jun 11;33(3). pii: e00042.
The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal - The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal
Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, Richardson DR. J Biol Chem. 2012 May 18;287(21):17016-28.